ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics


ClearPoint Neuro, Inc. (CLPT): $9.72

-0.12 (-1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLPT POWR Grades

  • Sentiment is the dimension where CLPT ranks best; there it ranks ahead of 81.31% of US stocks.
  • CLPT's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • CLPT ranks lowest in Quality; there it ranks in the 12th percentile.

CLPT Stock Summary

  • CLPT's price/sales ratio is 12.43; that's higher than the P/S ratio of 90.45% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.38 for CLEARPOINT NEURO INC; that's greater than it is for only 21.58% of US stocks.
  • With a year-over-year growth in debt of -40.75%, CLEARPOINT NEURO INC's debt growth rate surpasses merely 7.44% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CLEARPOINT NEURO INC, a group of peers worth examining would be AIRG, NSTG, KLTR, RXST, and DMRC.
  • Visit CLPT's SEC page to see the company's official filings. To visit the company's web site, go to www.clearpointneuro.com.

CLPT Valuation Summary

  • CLPT's price/sales ratio is 11.3; this is 438.1% higher than that of the median Healthcare stock.
  • CLPT's price/sales ratio has moved up 3.4 over the prior 130 months.

Below are key valuation metrics over time for CLPT.

Stock Date P/S P/B P/E EV/EBIT
CLPT 2023-01-30 11.3 5.6 -13.8 -13.6
CLPT 2023-01-27 12.4 6.1 -15.0 -14.9
CLPT 2023-01-26 11.7 5.8 -14.2 -14.1
CLPT 2023-01-25 11.8 5.8 -14.3 -14.2
CLPT 2023-01-24 11.4 5.6 -13.8 -13.6
CLPT 2023-01-23 11.8 5.8 -14.4 -14.2

CLPT Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -117.9%.
  • The 3 year price growth rate now stands at 111.64%.
  • Its year over year net cashflow from operations growth rate is now at -95%.
Over the past 33 months, CLPT's revenue has gone up $8,442,063.

The table below shows CLPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 19.659 -16.654 -16.199
2022-06-30 19.087 -16.098 -16.391
2022-03-31 17.3 -14.835 -15.831
2021-12-31 16.299 -12.697 -14.41
2021-09-30 15.73344 -11.547 -11.8429
2021-06-30 14.67863 -9.617486 -9.347127

CLPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLPT has a Quality Grade of C, ranking ahead of 36.69% of graded US stocks.
  • CLPT's asset turnover comes in at 0.297 -- ranking 130th of 186 Medical Equipment stocks.
  • ANGO, IVC, and MLSS are the stocks whose asset turnover ratios are most correlated with CLPT.

The table below shows CLPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.297 0.680 -0.308
2021-03-31 0.370 0.694 -0.245
2020-12-31 0.524 0.711 -0.240
2020-09-30 0.613 0.740 -0.337
2020-06-30 0.652 0.704 -0.416
2020-03-31 0.763 0.674 -0.596

CLPT Price Target

For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLPT Stock Price Chart Interactive Chart >

Price chart for CLPT

CLPT Price/Volume Stats

Current price $9.72 52-week high $16.96
Prev. close $9.84 52-week low $7.00
Day low $9.53 Volume 23,464
Day high $9.98 Avg. volume 72,028
50-day MA $9.06 Dividend yield N/A
200-day MA $10.79 Market Cap 238.67M

ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Sweden

The ClearPoint Prism™ Neuro Laser Therapy System The ClearPoint Prism™ Neuro Laser Therapy System SOLANA BEACH, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced enrollment of the first patient in a Glioblastoma clinical trial using the ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Lund, Sweden (SUS Lund). The Saf

Yahoo | December 12, 2022

ClearPoint Neuro (CLPT) Investor Presentation - Slideshow (NASDAQ:CLPT)

The following slide deck was published by ClearPoint Neuro, Inc.

Seeking Alpha | November 21, 2022

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Avidity Biosciences (RNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ClearPoint Neuro (CLPT – Research Report), Avidity Biosciences (RNA – Research Report) and Taysha Gene Therapies (TSHA – Research Report) with bullish sentiments. ClearPoint Neuro (CLPT) B.Riley Financial analyst Marc Wiesenberger maintained a Buy rating on ClearPoint Neuro today and set a price target of $18.50. The company's shares closed last Tuesday at $10.05. According to TipRanks.com, Wiesenberger is ranked #755 out of 8037 analysts. Currently, the analyst consensus on ClearPoint Neuro is a Moderate Buy with an average price target of $18.50.

Brian Anderson on TipRanks | November 9, 2022

ClearPoint Neuro: Great Execution During The Quarter (NASDAQ:CLPT)

ClearPoint Neuro continues to be priced at a premium today, although it can be a great investment in the long run. Read here for a detailed investment view.

Seeking Alpha | November 9, 2022

ClearPoint Neuro to Present at Upcoming Investor Conferences

SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the following investor conferences: 2022 Stifel Healthcare ConferencePresenting on Tuesday, November 15, 2022 at 10:55 a.m. Eastern Time in New York, NY. 34th Annual Piper Sandler Healthcare ConferencePresenting on Tuesday, November 29, 2022 at 1

Yahoo | November 9, 2022

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo 16.55%
3-mo -3.28%
6-mo -41.06%
1-year 12.11%
3-year 82.71%
5-year 224.00%
YTD 14.76%
2022 -24.51%
2021 -29.39%
2020 231.04%
2019 205.73%
2018 -42.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.84 seconds.